Hopstem Won First Place at 2024 SAPA Investment Forum & online Road Show with Innovative iPSC Cell Therapy for Chronic Stroke
Hopstem Biotechnology at 2024 CASSS CGPT Symposium
Hopstem Biotechnology to Participate in the 2024 BIO International Convention in San Diego
Hopstem to Showcase hNPC01 Clinical Data at 2024 ASGCT Annual Meeting in Baltimore
hNPC01, human iPSC-derived human forebrain neural progenitor cell product of Hopstem Biotech has been granted clinical approval treating hemiplegia sequelae after chronic ischemic stroke by FDA
Hopstem Biotechnology Announces First Patient Dosed in Phase I hNPC01 Clinical Trial
Hopstem Biotechnology Successfully Hold Initiation Meeting for hNPC01 Injection Clinical Trial at Xiangya Hospital
hNPC01, human iPSC-derived human forebrain neural progenitor cell product of Hopstem Biotech has been granted clinical approval treating hemiplegia sequelae after chronic ischemic stroke by CFDA
R&D Center: Building 11,Heda Medicine Valley V, Qiantang Area,
Hangzhou, Zhejiang, China
Manufacturing Center: 3rd & 4th Floor, Building 10,Heda Medicine Valley lll,
Qiantang Area, Hangzhou, Zhejiang, China
U.S. Office: 103 Carnegie center, Suite 300, Princeton,
NJ 08540, USA
